血浆D-二聚体及纤维蛋白（原）降解产物检测的临床意义

目的 探讨血浆D-二聚体和纤维蛋白（原）降解产物在临床不同血栓性疾病的诊断、疗效观察和预后判断中的应用价值.方法 选取2013年6-11月兰州大学第一医院住院病人257例作为疾病组,健康对照组34例,用酶联免疫荧光法、胶乳免疫比浊法对不同疾病患者的血浆D-二聚体和纤维蛋白（原）降解产物进行检测.结果 过敏性紫癜、脑梗死、肝硬化、原发性肝癌、急性粒细胞白血病、肺栓塞、静脉血栓形成等疾病患者血浆D-二聚体和纤维蛋白（原）降解产物增高,与健康对照组比较差异有统计学意义（P＜0.01）.结论 D-二聚体、纤维蛋白（原）降解产物检测有助于临床对患者高凝和纤溶状态的判断与治疗.

Detection of plasma D-dimer and fibrin/fibrinogen degradation products and its clinical significance

Objective To study the detection of plasma D-dimer and fibrin/fibrinogen degradation products in diagnosis, treatment and prognosis of thrombotic diseases. Methods Two hundred and fiifty-seven patients admitted to Lanzhou University No.1 Hospital from June 2013 to November 2013 served as a thrombotic disease group and 34 healthy subjects served as a control group in this study. Their plasma D-dimer and fibrin/fibrinogen degradation products were detected by ELISA and latex immune turbidimetric method, respectively. Results The plasma level of D-dimer and fibrin/fibdnogen degradation products was significantly higher in patients with allergic purpura, ischemic stroke, liver cirrhosis and primary liver cancer, acute myelocytic leukemia, pulmonary embolism and venous thrombosis than in healthy controls （DD： 0.28 ± 0.12 μ g/ml, FDPs： 1.87 ±1.17 μg/ml, P 〈 0.01）. Conclusion Detection of plasma D-dimer and fibrin/fibrinogen degradation products contribute to the diagnosis and treatment of thrombotic diseases.